{"filing":{"accession_number":"0001193125-26-371389","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-23","primary_document":"d124795d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526371389/d124795d8k.htm"},"events":[{"id":30080,"run_id":27566,"accession_number":"0001193125-26-371389","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Charles Ryan, the Company's President, is departing effective September 8, 2026. Although the disclosure mentions severance benefits under his Executive Change in Control and Severance Agreement, the principal disclosed action is the departure itself—a named executive officer leaving the organization. The severance arrangement is incidental to the departure event.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32583,"accession_number":"0001193125-26-371389","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Charles Ryan, the Company's President, is departing effective September 8, 2026. Although the disclosure mentions severance benefits under his Executive Change in Control and Severance Agreement, the principal disclosed action is the departure itself—a named executive officer leaving the organization. The severance arrangement is incidental to the departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:32:00.148561+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32583,"accession_number":"0001193125-26-371389","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Charles Ryan, the Company's President, is departing effective September 8, 2026. Although the disclosure mentions severance benefits under his Executive Change in Control and Severance Agreement, the principal disclosed action is the departure itself—a named executive officer leaving the organization. The severance arrangement is incidental to the departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:32:00.148561+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-08-27"}]}